Sponsored by:
.webp){kind=logo}
Intensification of Plasma-Derived IgG Manufacturing through an affinity-based purification platform
Maximize IgG yield with a simpler, scalable, and more sustainable purification approach
As global demand for plasma-derived IgG therapies continues to rise, manufacturers are under pressure to improve yield, efficiency, and sustainability. This white paper showcases how the Thermo Scientific™ CaptureSelect™ FcXP Affinity Matrix enables a modern affinity-based purification approach that simplifies traditional plasma fractionation workflows while delivering high-purity IgG with exceptional recovery.
Download this whitepaper to learn:
- High performance at scale: Achieved >90% IgG yield and >99% monomer purity across 100 cycles.
- Simplified purification workflow: Single-step affinity purification reduces reliance on complex ethanol-based fractionation.
- Consistent product quality: Maintained stable IgG subclass distribution with strong depletion of IgA, IgM, and FXIa impurities.
- Improved sustainability: Reduced ethanol usage supports safer and more environmentally friendly manufacturing.
- Flexible and scalable platform: Available on agarose or POROS™ bead supports to optimize for binding capacity or processing speed.
